Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) EBITDA (2023 - 2025)

Historic EBITDA for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$33.8 million.

  • Inhibrx Biosciences' EBITDA rose 2774.75% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year increase of 5834.88%. This contributed to the annual value of -$331.4 million for FY2024, which is 5119.35% down from last year.
  • As of Q3 2025, Inhibrx Biosciences' EBITDA stood at -$33.8 million, which was up 2774.75% from -$27.4 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year EBITDA high stood at -$27.4 million for Q2 2025, and its period low was -$160.9 million during Q2 2024.
  • In the last 3 years, Inhibrx Biosciences' EBITDA had a median value of -$46.3 million in 2023 and averaged -$61.1 million.
  • As far as peak fluctuations go, Inhibrx Biosciences' EBITDA crashed by 28921.6% in 2024, and later soared by 8297.74% in 2025.
  • Quarter analysis of 3 years shows Inhibrx Biosciences' EBITDA stood at -$88.3 million in 2023, then soared by 43.45% to -$49.9 million in 2024, then soared by 32.28% to -$33.8 million in 2025.
  • Its EBITDA was -$33.8 million in Q3 2025, compared to -$27.4 million in Q2 2025 and -$42.9 million in Q1 2025.